Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.

Lilly Endowment Inc. sold 3,196 shares of Eli Lilly & Co. common stock in multiple transactions on August 22, 2024.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a total of 3,196 shares of common stock on August 22, 2024.
• The sales were executed in multiple transactions at weighted average prices of $966.282 and $967.005 per share.
• The total number of shares sold at the first weighted average price was 2,996, and the total number of shares sold at the second weighted average price was 200.
• Following these transactions, Lilly Endowment Inc. beneficially owns 96,940,614 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any significant positive or negative sentiment. It is a neutral transaction.

Industry Context

This is a routine Form 4 filing, indicating a change in beneficial ownership by a major shareholder. Such filings are common and provide transparency into insider transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The transactions are relatively small compared to the total holdings of Lilly Endowment Inc., which is a common occurrence for large institutional investors.

Stakeholder Impact

• The share sale by Lilly Endowment Inc. is unlikely to have a significant impact on stakeholders due to the relatively small volume of shares sold.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, common stock, insider trading, beneficial ownership